Ko'krak bezi saratoni hind ayollarida tashxis qo'yilgan barcha saratonlarning 31% ni tashkil qiladi va bu saratonning etakchi turiga aylanadi. Eng yaxshi natijalarga erishish uchun ushbu jiddiy kasallik erta bosqichda davolanishi kerak. Bizning blogimiz ko'krak bezi saratoni haqida gapiradi.
2023 yil mart: Abemaciclib (Verzenio, Eli Lilly and Company) va endokrin terapiya (tamoksifen yoki aromataz inhibitori) oziq-ovqat va farmatsevtika idorasi (FDA) tomonidan kattalardagi bemorlarni adjuvant davolash uchun tasdiqlangan.
Feb 2023: Enhertu (trastuzumab deruxtecan) from AstraZeneca and Daiichi Sankyo has been approved as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received ..
2023-yil, fevral: 2021-yilda III darajali invaziv karsinoma (ko‘krak bezi saratoni) tashxisi qo‘yilgan Hamsa Nandini o‘zining sog‘lig‘i haqida Instagram’dagi obunachilarni yangiladi. Mirchi va Lege kabi telugu filmlarida suratga tushgan aktrisa..
Feb 2023: The Food and Drug Administration (FDA) has approved sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.) for people with hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+, or IHC 2+/ISH-) breast cance..
In February 2023, the Food and Drug Administration (FDA) approved elacestrant (Orserdu, Stemline Therapeutics, Inc.) for women or men over 50 who have advanced or metastatic breast cancer and are ER-positive, HER2-negative, and h..
2022 yil aprel: Rezektsiya qilib boʻlmaydigan yoki metastatik HER2-musbat koʻkrak bezi saratoni bilan ogʻrigan, metastatik sharoitda yoki neoadjuvant yoki adjuvant sharoitda ilgari anti-HER2 rejimini olgan va rivojlanayotgan kattalar bemorlar.
2022 yil mart: Oziq-ovqat va farmatsevtika idorasi olaparibni (Lynparza, AstraZeneca Pharmaceuticals, LP) BRCA mutatsiyaga uchragan (gBRCAm) zararli yoki shubhali zararli mikroblari bo'lgan kattalardagi bemorlarni adjuvant davolash uchun tasdiqladi.
2021 yil oktyabr: Oziq-ovqat va farmatsevtika idorasi abemaciclibni (Verzenio, Eli Lilly va Kompaniya) endokrin terapiyasi (tamoksifen yoki aromataza inhibitori) bilan birgalikda kattalar kasalliklari bilan og'rigan bemorlarni adjuvant davolash uchun tasdiqladi.
2021 yil avgust: Pembrolizumab (Keytruda, Merck) FDA tomonidan yuqori xavfli, erta bosqichli uch salbiy ko'krak bezi saratoni (TNBC) uchun kimyoterapiya bilan birgalikda neoadjuvant davo sifatida, keyinchalik esa yordamchi vosita sifatida tasdiqlangan.